Standard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this ...
“Our study reveals that a significant portion of patients at the extremes of older age still derive benefit from the VEN-HMA regimen – which is the standard of care for older AML patients and those ...
Intensive induction chemotherapy and HMA/VEN showed similar adjusted survival outcomes in older patients with NPM1-mutant AML. Composite complete remission rates were comparable between IC and HMA/VEN ...
The combination of venetoclax (VEN) and a hypomethylating agent (HMA) is a standard of care for patients with AML and higher-risk myelodysplastic syndromes (MDS). However, real-world outcomes data ...
Standard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results